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Abstract
Objectives—To determine the frequency, accrual, attribution and outcome of neuropsychiatric
(NP) events and impact on quality of life over 3 years in a large inception cohort of SLE patients.
Methods—The study was conducted by the Systemic Lupus International Collaborating Clinics.
Patients were enrolled within 15 months of SLE diagnosis. NP events were identified using the ACR
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case definitions and decision rules were derived to determine the proportion of NP disease attributable
to SLE. The outcome of NP events was recorded and patient perceived impact determined by the
SF-36.
Results—There were 1206 patients (89.6% female) with a mean (±SD) age of 34.5±13.2 years.
The mean disease duration at enrollment was 5.4±4.2 months. Over a mean follow-up of 1.9±1.2
years 486/1206 (40.3%) patients had ≥1 NP events which were attributed to SLE in 13.0%–23.6%
of patients using two a priori decision rules. The frequency of individual NP events varied from
47.1% (headache) to 0% (myasthenia gravis). The outcome was significantly better for those NP
events attributed to SLE especially if they occurred within 1.5 years of the diagnosis of SLE. Patients
with NP events, regardless of attribution, had significantly lower summary scores for both mental
and physical health over the study.
Conclusions—NP events in SLE patients are variable in frequency, most commonly present early
in the disease course and adversely impact patients’ quality of life over time. Events attributed to
non-SLE causes are more common than those due to SLE, although the latter have a more favourable
outcome.
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The frequency of neuropsychiatric (NP) disease in systemic lupus erythematosus (SLE) varies
between 37%–95% (1–5). Differences in the definition and ascertainment of NP
manifestations, lack of consistency in the attribution of NP events and inclusion of subtle NP
disease of uncertain clinical significance contribute to this variability. The fluctuating course
of many NP manifestations emphasizes the need to evaluate their impact over time.
An international, multi-center, prospective, inception cohort study of NP events in SLE patients
was undertaken using uniform definitions, diagnostic criteria determination of attribution. We
previously reported on NP events at enrollment (6) including short-term outcome over a mean
of 3.7 months. Here we report the clinical characteristics, outcome and impact on health-related
quality of life (HRQOL) in an expanded cohort of patients evaluated over three years and up
to 4 annual assessments with a mean follow-up of 23 months.
Patients and Methods
Research network
The study was performed by the Systemic Lupus International Collaborating Clinics (SLICC)
(7) between October 1999 and February 2008. The study was approved by the Capital Health
Research Ethics Board, Halifax, Nova Scotia, Canada and by the institutional research ethics
boards of participating centers..
Patients
Patients fulfilled the American College of Rheumatology (ACR) classification criteria for SLE
(8) and provided written informed consent. The date of diagnosis was when ≥4 ACR criteria
were first recognized and enrollment occurred up to 15 months following the diagnosis. Patients
were reviewed at enrollment and annually (±6 months) thereafter when new NP events since
the previous visit and the status of old events were recorded. Other data included age, gender,
ethnicity, education, medication use, SLE Disease Activity Index (SLEDAI) (9) and SLICC/
ACR damage index (SDI) (10). HRQOL was measured by the SF-36 (11). Laboratory data
included a complete blood count, serum creatinine, urinalysis, anti-DNA, C3 and C4.
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All NP events were characterized using the ACR case definitions and were diagnosed by
clinical evaluation supported with appropriate investigations as per the ACR glossary (12) (See
appendix #1). The exception was cognitive impairment for which the diagnosis was made by
formal neuropsychological testing in only 9/43 (21%) of cases.
Outcome of NP events
A physician generated 7-point Likert scale compared the change in NP status between the onset
of the event and time of study assessment (1=patient demise, 2=much worse, 3=worse, 4=no
change, 5=improved, 6=much improved, 7=resolved).The time to resolution was the interval
between the onset of the event and the date of resolution; if the NP event had not resolved the
time was censored to onset of the event and the date of the final assessment. Analyses of both
time to resolution and Likert outcome scores were undertaken. A patient generated mental
(MCS) and physical (PCS) component summary score of the SF-36 (11) determined the impact
of NP events on HRQOL.
Statistical analysis
NP events were attributed to SLE or non-SLE causes (See appendix #1). and categorized into
central/peripheral and diffuse/focal nervous system manifestations as described (6, 12) (See
appendix #2). SLICC centers were grouped into geographic locations (Canada, U.S.A./Mexico,
Europe, Asia). For some analyses patients were categorized at each assessment as NP positive
with (a) diffuse/central events only, (b) focal/peripheral events only, (c) both events, and (d)
a NP negative group.
Chi-square and t-tests examined differences in demographics and NP status at enrollment
between patients with missing data and patients who completed the study. Explanatory
variables for time-to-case resolution for NP events were examined using Cox regression
(adjusting for correlation of events in the same patient).
Likert outcome scores of NP events were analyzed using multi-level ordinal logistic regression,
with odds ratios linked to the probability of higher, more favourable, scores, and accounting
for correlation of multiple scores over time for the same event and multiple events for the same
patient. SF-36 analyses utilized linear regression and generalized estimating equations with a
first-order autoregressive correlation structure to allow for correlation between multiple SF-36
measurements for the same patient.
Results
Patients
1206 patients were recruited in 24 centers. Patients were predominantly female (89.6%) and
Caucasian with a mean±SD age of 34.5±13.2 years (Table 1).
The mean disease duration was 5.4±4.2 months in an unselected patient population with
moderate disease activity. The mean follow-up for NP events (the onset of NP events to the
last assessment) was 1.9±1.2 years. No follow-up was available in 191/1206 (15.8%) patients
and the assessment for the last anticipated date plus 6 months was unavailable in 353/1206
(29.3%). These patients were more likely to be younger (p<0.008), Hispanic or Black
(p<0.0001), had less education (p<0.006) and higher SLEDAI scores (6.1±6.3 vs. 5.2±5.2;
p<0.023). They were also less likely to have NP disease, attributed to SLE or non-SLE causes,
at the enrollment assessment (p<0.023). There were 18/1206 (1.5%) deaths and in 4/18 (22.2%)
the primary cause was attributed to NP events (intracranial hemorrhage (2), stroke (1), seizures
(1)).
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Frequency and attribution of NP events
486 of 1206 (40.3%) patients had at least one NP event during the study. 210 (17.4%) had two
or more events. The 486 patients had 843 events encompassing 18/19 NP syndromes (Table
2).
The most frequent events were headache (migraine (49%), tension (38%), intractable 9%,
cluster (3%), pseudotumour cerebri (1%),), mood disorders, seizures, cognitive dysfunction,
anxiety disorder, cerebrovascular disease, acute confusional state, polyneuropathy and
mononeuropathy. The remaining 10 NP syndromes had a prevalence of less than 2%;
myasthenia gravis did not occur in any patient.
NP events attributed to SLE varied from 17.7% (model A) to 30.6% (model B) (Table 2). Of
the 843 NP events 785 (93.1%) affected the central nervous system and 58 (6.9%) involved
the peripheral nervous system. Diffuse and focal events were 666 (79%) and 177 (21%),
respectively. The most frequent NP events attributed to SLE were seizures, mood disorders,
cerebrovascular disease and acute confusional states.
Onset and accrual of NP events
NP events were most frequent at the enrollment visit and the cumulative frequency of both
SLE and non-SLE NP events increased over time (Figure 1). Of patients with follow-up to the
final study assessment, 51.2% had at least one NP event. The proportion of patients with NP
events attributed to SLE varied between 13.0% (model A) and 23.6% (model B). The
proportion of patients with both SLE and non-SLE attributed NP events was 7.9% (model A)
and 14.2% (model B).
Outcome of NP events
There was no difference in the attribution frequency of new, recurring or ongoing NP events
(Figure 2). However, the rate of resolution of NP events attributed to SLE was higher than
events due to non-SLE causes (model A: 55.0%vs.38.2%, hazard ratio (HR): 1.62, 95% CI=
[1.24,2.11], p<0.001; model B: 51.9%vs.36.4%, HR: 1.53, 95% CI=[1.22,1.92], p<0.001).
There was a higher resolution of focal vs. diffuse NP events (52.5%vs.38.1%, HR: 1.55, 95%
CI=[1.21,1.98], p<0.001) but no difference between the resolution of central vs. peripheral NP
events (41.4%vs.37.9%, HR: 1.23, 95% CI=[0.79,1.93], p=0.358).
To look for an interaction between disease duration and the effect of attribution on NP event
resolution, disease duration at the occurrence of events was dichotomized at 1.5 years. For
model A the estimated SLE attribution effect on resolution of events within 1.5 years of the
diagnosis of SLE was larger than the effect for events occurring ≥1.5 years following the
diagnosis (HR: 1.77vs. 0.89) (interaction coefficient=−0.69, 95%CI=[−1.52, 0.15], p=0.107).
For model B, the same analysis led to a hazard ratio comparison of: 1.66vs.0.86 (interaction
coefficient=−0.66, 95%CI=[−1.39,0.07], p=0.076).
Favorable Likert outcome scores for NP events were more frequent for those attributed to SLE
(model A or model B), particularly at the first two study assessments (Figure 3). Controlling
for the duration of follow-up, multivariate ordinal regression analysis confirmed a significant
positive association between favorable outcome scores and SLE NP events (model B) (odds
ratio (OR): 1.51, 95%CI=[1.05, 2.21], p=0.028), focal NP events (OR: 1.83, 95%CI=[1.28,
2.64], p=0.001), US/Mexico (OR: 1.32, 95%CI=[0.90, 1.93]), European (OR: 1.66, 95%CI=
[1.12,2.46]), and Asian (OR: 2.79, 95%CI=[1.41,5.50]) sites (p=0.007), and negative
associations with older age at SLE diagnosis (OR: 0.69, 95%CI=[0.59,0.81]), p<0.001), longer
disease duration at event onset (OR: 0.79, 95%CI=[0.69,0.90]), p=0.001) and higher SLEDAI
scores computed without NP variables (OR: 0.95, 95%CI=[0.93, 0.98]), p=0.002), all of which
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were included in the models as continuous variables. The interaction between disease duration
at event onset and attribution of an NP event was again only marginally significant (p = 0.095).
NP events and HRQOL
In a multivariate regression analysis there were significantly lower MCS scores in patients with
NP events regardless of attribution compared to those without events (estimate: −9.7, 95%CI=
[−12.7,−6.7]; p<0.001) (Figure 4). Controlling for gender, age at SLE diagnosis, disease
duration at each visit, a summary multivariate analysis also demonstrated associations between
lower MCS scores and diffuse NP events (e.g. patients with diffuse vs. focal NP events only:
estimate=−5.0, 95%CI=[−9.2,−0.8]; global p = 0.041), higher SLEDAI scores (estimate: −0.15,
95%CI=[−0.30,−0.01], p=0.041) and higher SDI scores, both computed without NP variables
(e.g., SDI >3 vs. <=3: estimate=−5.7, 95%CI=[−10.4,−0.9]; global p=0.039). Similarly the
group means for the PCS scores were significantly lower in patients with NP events (estimate:
−3.3, 95%CI=[−4.5,−2.1], p<0.001) regardless of attribution (Figure 4). In a summary
multivariate analysis controlling for ethnicity, age at SLE diagnosis and disease duration at
each visit, other significant associations with lower PCS scores were with study sites (e.g., US/
Mexico vs. rest: estimate: −5.3, 95%CI=[−7.2, −3.4]; global p<0.001), female gender
(estimate: −2.3, 95%CI=[−4.3,−0.3], p=0.024), lack of college education (estimate: −2.7, 95%
CI=[−4.1,−1.3], p<0.001), higher SLEDAI scores (estimate: −0.35, 95%CI=[−0.48,−0.22],
p<0.001) and higher SDI scores (e.g., SDI >3 vs. <=3: estimate: −5.2, 95%CI=[−8.9,−1.5];
global p<0.001) computed without NP variables.
Discussion
We have established a large, SLE disease inception cohort for the systematic evaluation of NP
events in a long-term prospective study. A unique feature of the study is inclusion of all NP
events regardless of the etiology, so that differences in the outcome and impact of NP events
due to SLE and other causes could be compared. Attribution of NP events was determined
using predefined decision rules which have previously provided a positive correlation between
SLE NP events and pathogenic autoantibodies (13). Over the study 40.3% of patients had at
least one NP event and 17.4% had multiple events. However, patients with NP events attributed
to SLE varied from 13.0% to 23.6%, depending upon the stringency of the attribution rules.
Likewise, only 17.7% to 30.6% of all NP events were attributed to SLE. Finally, many of the
19 syndromes occurred in less than 2% of patients, indicating that they are relatively infrequent,
at least in the first 3 years of the disease.
The outcome of NP events in SLE patients, particularly those attributed directly to SLE, has
been informed by clinical trials (14–19), retrospective and prospective observational cohorts
and case series (20) (21) with inconsistent results. In the current study the most favorable
outcomes occurred with NP events attributed to SLE compared to non-SLE causes and with
focal NP compared to diffuse NP events. Furthermore, the outcome was best in SLE attributed
events when they occurred early in the disease course, suggesting that the attribution and time
of onset of NP events predict outcome. As for rheumatoid arthritis (22,23) this may indicate a
therapeutic window of opportunity when pathogenetic mediators are amenable to
immunosuppressive and anti-inflammatory therapies. The current study confirms and expands
the findings of previous cross-sectional studies reporting that NP events, regardless of
attribution, are associated with a significant reduction in patient self-report HRQOL (3,24,
25). Thus, in addition to lower group means for MCS and PCS scores of the SF-36 in patients
with NP events compared to those without NP events at enrollment, the same group differences
persist over the ensuing three years. Our results also emphasize the importance of assessing
the impact of all NP manifestations as studies confined to specific subsets of NP disease such
as cognitive dysfunction have not found a negative effect on HRQOL (26,27).
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There are potential limitations to our study. First, the frequency of patients with unavailable
data (29%) or no follow-up (15.8%) by the final study assessment is high compared to some
longitudinal lupus cohorts with rates as low as 11% (28,29). However these cohorts were more
homogenous and followed at single centers. In contrast, a 29% lost to follow-up over 3.5 years
was reported in a large, multi-ethnic, multi-center cohort with very similar predictors as in our
study (30). Second, restricting NP syndromes to the 19 ACR case definitions (12) could have
excluded some NP presentations. However, none of the 1206 patients had an NP event which
could not be captured within the ACR definitions. Finally, formal neuropsychological
assessments were not performed on all patients and neuroimaging studies were only done if
clinically indicated. Although additional abnormalities would likely have been detected by
both techniques, our protocol was intended to reflect clinical practice and to avoid the inclusion
of subtle NP disease with limited clinical significance (26,31–36).
In summary our findings indicate a high cumulative frequency of NP events and a negative
impact on HRQOL, even though the majority of NP events are not attributable to SLE. Those
events attributed to SLE and focal NP events have a better outcome. Future studies will examine
the long-term course and impact of nervous system disease and search for biomarkers and
pathogenic mechanisms of NP events in this unique cohort of SLE patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The cumulative frequency of patients with NP events at enrollment and at subsequent study
assessments. The percentage of patients with NP events is shown at each time point for all NP
events regardless of attribution (all NP), NP events attributed to non-SLE causes (non-SLE
NP), NP events attributed to SLE as per attribution model B (SLE NP (B)) and NP events
attributed to SLE as per attribution model A (SLE NP (A)).
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The frequency of NP events at enrollment and at subsequent study assessments characterized
as new, recurring or ongoing from a previous assessment. At each assessment the status of the
NP events into resolved or unresolved is shown. Summary data is shown for NP events
regardless of attribution (all NP events), NP events attributed to SLE as per attribution model
A (SLE NP (A)), NP events attributed to SLE as per attribution model B (SLE NP (B)) and
NP events attributed to non-SLE causes (non-SLE NP).
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The outcome of NP events over the duration of the study. Events are clustered into all NP
events regardless of attribution (all NP events), NP events attributed to SLE as per attribution
model A (SLE NP events (model A)), NP events attributed to SLE as per attribution model B
(SLE NP events (model B)) and NP events attributed to non-SLE causes (non-SLE NP events).
Within each panel the outcome of the events is scored as much worse, worse, no change,
improved, much improved and resolved at assessments 1 through 4 compared to the onset of
the event.
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Mean MCS and PCS of the SF-36 over the period of study in patients with no NP events (NP
negative), NP events attributed to non-SLE causes (non-SLE NP) and NP events attributed to
SLE as per attribution model A or B (SLE NP A or B) at each of the study assessments. (See
appendix #3).
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Table 1
Demographic and clinical manifestations of SLE patients at enrollment visit
Number of Patients 1206
Gender, n, (%) Female 1080 (89.6)
Male 126 (10.5)
Age (years) (mean ± SD) at enrollment 34.5 ± 13.2










Post secondary education, % 62.1
Disease duration (months) (mean ± SD) 5.4 ± 4.2
Number of ACR criteria (mean ± SD) 4.5 ±1.01
Cumulative ACR manifestations, n, %
Malar rash 501 (41.5)
Discoid rash 174 (14.4)
Photosensitivity 434 (35.9)
Oral/nasopharyngeal ulcers 539 (44.7)
Serositis 336 (27.8)
Arthritis 886 (73.5)
Renal disorder 346 (28.7)
Neurological disorder 71 (5.9)
Hematologic disorder 742 (61.5)
Immunologic disorder 923 (76.5)
Antinuclear antibody 1158 (96.0)
SLEDAI score (mean ± SD) 5.4 ± 5.5
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